论文部分内容阅读
目的观察索拉非尼治疗晚期肝癌(HCC)的有效性和安全性。方法 20例老年晚期HCC患者口服索拉非尼单药治疗(400mg,每日2次),至疾病进展或出现不可耐受的毒副反应,每6周按照RECIST标准(1.0版)进行疗效评价,按NCI-CTC(3.0版)评价毒副反应并动态监测甲胎蛋白(AFP)的变化和随访生存情况。结果在19例可评价的患者中获得SD12例,PD7例,疾病控制率(DCR)为63.2%,中位疾病进展时间(mTTP)为3.8个月(95%CI:2.54～5.06个月)中位总生存期(mOS)为6.0个月(95%CI:3.94～8.06个月),治疗前12例AFP高于正常,治疗后明显下降3例,稳定4例,升高5例。主要不良反应为手足皮肤反应、食欲下降和腹泻。结论索拉非尼治疗老年晚期肝癌有效毒副反应可耐受。值得进一步观察。
Objective To observe the efficacy and safety of sorafenib in the treatment of advanced hepatocellular carcinoma (HCC). Methods Twenty patients with advanced HCC received oral single-dose sorafenib (400 mg twice daily) until the disease progressed or became intolerant. The response to RECIST criteria (version 1.0) was evaluated every 6 weeks According to the NCI-CTC (version 3.0), the side effects were evaluated and the AFP changes and follow-up were monitored dynamically. Results Among the 19 evaluable patients, SD12 and PD7 were obtained, the disease control rate (DCR) was 63.2% and the median time to progression (mTTP) was 3.8 months (95% CI: 2.54 to 5.06 months) The median overall survival (mOS) was 6.0 months (95% CI: 3.94 to 8.06 months). Before treatment, AFP in 12 patients was significantly higher than that in normal subjects. Three patients were significantly decreased after treatment, 4 patients were stable and 5 patients were elevated. The main adverse reactions were hand-foot skin reaction, loss of appetite and diarrhea. Conclusion Sorafenib treatment of elderly patients with advanced liver cancer effective side effects are tolerable. Worth further observation.